



M M REDDY & CO.,
Chartered Accountants

Phone : 040-23418836
040-40272617
Mobile : 98482 71555

Auditor's Report On Quarterly Standalone Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

Board of Directors

SAAMYA BIOTECH (INDIA) LIMITED We have audited the quarterly financial results **SAAMYA BIOTECH (INDIA) LIMITED** for the quarter ended March 31, 2018 and for the year ended, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34 for 'Interim Financial Reporting', specified under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us, these quarterly standalone financial results, as well as the year to date results: _

(i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and

(ii) give a true and fair 'view of the total comprehensive income (comprising of net profit and other comprehensive income) and other financial information for the quarter ended March 31, 2018 and for the year then ended.

For M M REDDY & CO.,

Chartered Accountants

Firm Registration No.: 0103715

M MADHUSUDHANA REDDY
Partner

Membership No. 213077



PLACE: HYDERABAD

DATE: 30/05/2018



Saamya Biotech (India) Ltd.

CIN: L24239AP2002PLC039449

May 31, 2018

To

Corporate Relations Department,
BSE LTD,
P J Towers,
Dalal Street,
Mumbai - 400001.

Sirs,

Sub: Q4 Unaudited Financial Results – Reg...

Ref: Scrip Code – 532905


Please find herewith attached Un-audited financial results for the Fourth quarter ending 31th March 2018 along with Limited Review Report. The Board Meeting Commenced at 4 PM and concluded at 5:15 PM. Please take on record the same.

Thanking You,

For SAAMYA BIOTECH (INDIA) LIMITED

U. Hanisudhan Reddy

Director



Corporate Office: Plot No. 391- D. Road No 81, Phase - III, Jubilee Hills, Hyderabad - 500 033, A.P., India. Tel: +91-40-2355 1601 / 1604.
Fax: +91-40-2354 1127, email: info@saamyabiotech.com, saamyabiotechltd@yahoo.com, Webiste: www.saamyabiotech.com

Regd. Office: Suite 104-106, Lumbini Enclave, Opp. NIMS, Punjagutta, Hyderabad - 500 082, A.P., India. Tel: +91-40-2339 9832 / 9241
Fax: +91-40-2339 5214 e-mail : saamyaindia@saamyabiotech.com



Saamya Biotech (India) Ltd.

SCHEDULE III OF COMPANIES ACT, 2013					
PART II - AUDITED STANDALONE & CONSOLIDATED STATEMENT OF PROFIT AND LOSS FOR QUARTER IV AND YEAR ENDED 31ST MARCH, 2018					
Amounts in Lakhs					
Particulars	STANDALONE FINANCIALS				
	Quarter Ended			Year Ended	
	3 Months Ended 31/03/2018	Preceding 3 Months Ended 31/12/2017	Corp. 3 months ended 31/03/2017	31-03-18	31-03-17
	Audited	Unaudited	Audited	Audited	Audited
I Revenue from Operations	-	-	-	-	-
II Other Income	-	-	-	-	-
III Total Revenue (I+II)	-	-	-	-	-
IV Expenses	-	-	-	-	-
Cost of Material Consumed	-	-	-	-	-
Purchase of Stock-in-trade	-	-	-	-	-
Changes in inventories of finished goods, Work in progress and Stock in trade	-	-	-	-	-
Employee benefits expense	0.46	0.48	2.49	2.03	9.66
Finance Costs	-	-	-	-	936.63
Depreciation and Amortisation expense	0.25	0.25	869.13	1.00	3,165.57
Other Expense	0.71	0.73	4,029.95	3.03	4,111.86
Total Expenses	0.71	0.73	4,029.95	3.03	4,111.86
V Profit/(Loss) from before Prior Period Expenses and tax (I-IV)	(0.71)	(0.73)	(4,029.95)	(3.03)	(4,111.86)
VI Prior Period Expenses	-	-	-	-	-
VII Profit/(Loss) before tax (V-VI)	(0.71)	(0.73)	(4,029.95)	(3.03)	(4,111.86)
VIII Tax Expense:	-	-	-	-	-
Current Tax	-	-	-	-	-
Deferred Tax	-	-	-	-	-
IX Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(0.71)	(0.73)	(4,029.95)	(3.03)	(4,111.86)
X Profit/ (Loss) from discontinuing operations	-	-	-	-	-
XI Tax Expense of discontinuing operations	-	-	-	-	-
XII Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-	-
XIII Profit/ (Loss) for the period (IX+XII)	(0.71)	(0.73)	(4,029.95)	(3.03)	(4,111.86)
XIV Other Comprehensive Income A) (i) Items that will not be reclassified to profit or loss (ii) Income Tax related to items that will not be reclassified to profit or loss (B) (i) Items that will be reclassified to profit or loss (ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XV Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(0.71)	(0.73)	(4,029.95)	(3.03)	(4,111.86)
XVI Earnings Per Equity Share (For Continuing Operations) (Face Value INR 2/- each)	(0.00)	(0.00)	(16.20)	(0.01)	(16.53)
1) Basic	-	-	-	-	-
2) Diluted	-	-	-	-	-
XVII Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 2/- each)	-	-	-	-	-
1) Basic	-	-	-	-	-
2) Diluted	-	-	-	-	-
XVIII Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 2/- each)	(0.00)	(0.00)	(16.20)	(0.01)	(16.53)
1) Basic	-	-	-	-	-
2) Diluted	-	-	-	-	-
XIX Paid Up Equity Share Capital (Face Value of INR 2/- per share)	2,488.25	2,488.25	2,488.25	2,488.25	2,488.25
XX Reserves & Surplus (Excluding Revaluation Reserve)	-	-	-	-	-

Notes:

- In pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013, the above Financial Results have been prepared, reviewed by the Statutory Auditors of Company and recommended by Audit Committee and subsequently approved by Board of Directors of Company at their meeting held on 30th of May, 2018.
- The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS prescribed under Section 133 of Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended).
- The figures of the previous year/periods have been re-grouped/re-classified, whenever necessary, for the purpose of comparison.
- The figures of the current quarter ended 31st March, 2018 and the quarter ended 31st March, 2017 are the balancing figures between the audited figures in respect of the full financial year ended respectively and published unaudited year-to-date figures upto the third quarter of the respective financial years.
- The results are also available on the website of the Company; www.visuglcbaledu.com
- The Company is engaged in "Research and Development of Bio-technology Products" operating hence there are no separate reportable segments as per Ind AS - 108 "Operating Segments"

For SAAMYA BIOTECH (INDIA) LIMITED

G. Hanumantharao
Wholtime Director





Saamya Biotech (India) Ltd.

SCHEDULE III OF COMPANIES ACT, 2013					
PART II - AUDITED STANDALONE & CONSOLIDATED STATEMENT OF PROFIT AND LOSS FOR QUARTER IV AND YEAR ENDED 31ST MARCH, 2018					
Amounts in Lakhs					
Particulars	STANDALONE FINANCIALS				
	Quarter Ended			Year Ended	
	3 Months Ended 31/03/2018	Preceding 3 Months Ended 31/12/2017	Corp. 3 months ended 31/03/2017	31-03-18	31-03-17
	Audited	Unaudited	Audited	Audited	Audited
I Revenue from Operations	-	-	-	-	-
II Other Income	-	-	-	-	-
III Total Revenue (I+II)	-	-	-	-	-
IV Expenses	-	-	-	-	-
Cost of Material Consumed	-	-	-	-	-
Purchase of Stock-in-trade	-	-	-	-	-
Changes in inventories of finished goods, Work in progress and Stock in trade	-	-	-	-	-
Employee benefits expense	0.46	0.48	2.49	2.03	9.66
Finance Costs	-	-	-	-	936.63
Depreciation and Amortisation expense	-	-	869.13	-	3,165.57
Other Expense	0.25	0.25	3,158.33	1.00	4,111.86
Total Expenses	0.71	0.73	4,029.95	3.03	4,111.86
V Profit/(Loss) from before Prior Period Expenses and tax (I-IV)	(0.71)	(0.73)	(4,029.95)	(3.03)	(4,111.86)
VI Prior Period Expenses	-	-	-	-	-
VII Profit/(Loss) before tax (V-VI)	(0.71)	(0.73)	(4,029.95)	(3.03)	(4,111.86)
VIII Tax Expense:	-	-	-	-	-
Current Tax	-	-	-	-	-
Deferred Tax	-	-	-	-	(4,111.86)
IX Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(0.71)	(0.73)	(4,029.95)	(3.03)	(4,111.86)
X Profit/ (Loss) from discontinuing operations	-	-	-	-	-
XI Tax Expense of discontinuing operations	-	-	-	-	-
XII Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-	-
XIII Profit/ (Loss) for the period (IX+XII)	(0.71)	(0.73)	(4,029.95)	(3.03)	(4,111.86)
XIV Other Comprehensive Income A) (i) Items that will not be reclassified to profit or loss (ii) Income Tax related to items that will not be reclassified to profit or loss (B) (i) Items that will be reclassified to profit or loss (ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XV Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(0.71)	(0.73)	(4,029.95)	(3.03)	(4,111.86)
XVI Earnings Per Equity Share (For Continuing Operations) (Face Value INR 2/- each)	(0.00)	(0.00)	(16.20)	(0.01)	(16.53)
1) Basic	-	-	-	-	-
2) Diluted	-	-	-	-	-
XVII Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 2/- each)	-	-	-	-	-
1) Basic	-	-	-	-	-
2) Diluted	-	-	-	-	-
XVIII Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 2/- each)	(0.00)	(0.00)	(16.20)	(0.01)	(16.53)
1) Basic	-	-	-	-	-
2) Diluted	-	-	-	-	-
XIX Paid Up Equity Share Capital (Face Value of INR 2/- per share)	2,488.25	2,488.25	2,488.25	2,488.25	2,488.25
XX Reserves & Surplus (Excluding Revaluation Reserve)	-	-	-	-	-

Notes:


- In pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013, the above Financial Results have been prepared, reviewed by the Statutory Auditors of Company and recommended by Audit Committee and subsequently approved by Board of Directors of Company at their meeting held on 30th of May, 2018.
- The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS prescribed under Section 133 of Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended).
- The figures of the previous year/periods have been re-grouped/re-classified, whenever necessary, for the purpose of comparison.
- The figures of the current quarter ended 31st March, 2018 and the quarter ended 31st March, 2017 are the balancing figures between the audited figures in respect of the full financial year ended respectively and published unaudited year to date figures upto the third quarter of the respective financial years.
- The results are also available on the website of the Company: www.visuglcbaledu.com
- The Company is engaged in "Research and Development of Bio-technology Products" operating hence there are no separate operating segments as per Ind AS - 108 "Operating Segments"

For SAAMYA BIOTECH (INDIA) LIMITED

U. Hanumanth Rao

Wholtime Director

Place: Hyderabad
Date: 30.05.2018



Corporate Office: Plot No. 391- D. Road No 81, Phase - III, Jubilee Hills, Hyderabad - 500 033, A.P., India. Tel: +91-40-2355 1601 / 1604.
Fax: +91-40-2354 1127, email: info@saamyabiotech.com, saamyabiotechltd@yahoo.com, Webiste: www.saamyabiotech.com
Regd. Office: Suite 104-106, Lumbini Enclave, Opp. NIMS, Punjagutta, Hyderabad - 500 082, A.P., India. Tel: +91-40-2339 9832 / 9241
Fax: +91-40-2339 5214 e-mail : saamyaindia@saamyabiotech.com



Saamya Biotech (India) Ltd.

SAAMYA BIOTECH(INDIA) LIMITED
BALANCE SHEET AS AT 31st MARCH 2018


(Amount Rs.Lacs)

PARTICULARS		Note No.	As at March 31, 2018	As at March 31, 2017	As at April 1st, 2016
I ASSETS:					
(1) Non-current assets					
(a) Property, Plant and Equipment					
		2	17.26	17.26	953.90
(b) Capital work-in-progress					
			1,825.98	1,825.98	1,824.91
(c) Goodwill					
			-	-	-
(d) Other Intangible Assets					
			-	-	-
(e) Intangible Assets under development					
			-	-	-
(f) Biological Assets					
			-	-	-
(g) Financial assets					
(i) Investments					
		3	0.89	0.89	0.89
(ii) Other Financial Assets					
		4	-	-	-
(h) Deferred tax assets (net)					
			-	-	51.91
(i) Other non-current assets					
		5	15.98	15.98	15.98
(2) Current assets					
(a) Inventories					
		6	-	-	-
(b) Financial assets					
(i) Investments					
			-	-	-
(ii) Trade receivables					
		7	-	-	-
(iii) Cash and cash equivalents					
		8	1,860.77	1,860.77	5,017.90
(iv) Bank Balances other than (iii) above					
			0.87	0.90	1.71
(v) Loans and advances					
		9	-	-	-
(vi) Investments held for Sale					
			65.51	65.51	65.51
(c) Other current assets					
		10	-	-	-
TOTAL ASSETS			3,787.26	3,787.29	7,932.71
II EQUITY AND LIABILITIES:					
Equity					
(a) Equity Share Capital					
		11	2,488.25	2,488.25	2,488.25
(b) Other Equity					
(ii) Reserves and Surplus					
		12	(3,829.88)	(3,826.85)	337.28
Liabilities					
(1) Non Current Liabilities					
(a) Financial Liabilities					
(i) Borrowings					
		13	324.00	324.00	324.00
(b) Deferred tax liabilities (Net)					
		14	-	-	-
(2) Current Liabilities					
(a) Financial Liabilities					
(i) Borrowings					
		15	-	-	-
(ii) Trade Payables					
		16	4,681.65	4,679.65	4,680.08
(iii) Other financial liabilities					
			-	-	-
(b) Other current liabilities					
		17	7.86	7.86	7.86
(c) Provisions					
		18	115.38	114.38	95.24
(d) Current tax liabilities(Net)					
			-	-	-
TOTAL EQUITY AND LIABILITIES			3,787.26	3,787.29	7,932.71

For SAAMYA BIOTECH (INDIA) LIMITED

U. Kiraneshwar Reddy
Wholetime Director

Date : 30-05-2018



Corporate Office: Plot No. 391- D. Road No 81, Phase - III, Jubilee Hills, Hyderabad - 500 033, A.P., India. Tel: +91-40-2355 1601 / 1604.
Fax: +91-40-2354 1127, email: info@saamyabiotech.com, saamyabiotechltd@yahoo.com, Webiste: www.saamyabiotech.com
Regd. Office: Suite 104-106, Lumbini Enclave, Opp. NIMS, Punjagutta, Hyderabad - 500 082, A.P., India. Tel: +91-40-2339 9832 / 9241
Fax: +91-40-2339 5214 e-mail : saamyaindia@saamyabiotech.com